Gastrointestinal tolerability remained the dominant adverse-reaction cluster, aligning with established GLP‑1 receptor agonist class effects across dose ranges. A higher-dose signal of altered skin ...
Novo Nordisk said on Thursday the U.S. Food and Drug Administration has approved a higher dose of its blockbuster ...
Opinion
Worcester Telegram on MSNOpinion
Opinion/Guest column: Fastest route to FDA approval not the best
The strength and credibility of the FDA relies on maintaining a clear line between evidence-based, scientific rigor and political priority setting.
While many in the biotechnology sector expressed excitement for faster drug approval timelines, some researchers voiced concerns that critical data review could be missed.
An FDA complete response letter for idebenone in LHON indicates unresolved NDA deficiencies and necessitates additional data before approval can be reconsidered. Priority review status and a February ...
17d
Scholar Rock outlines 2026 apitegromab BLA resubmission and commercial launch following FDA progress
FDA reinspection, apitegromab BLA resubmission and 2026 launch outlook, plus cash and new debt facility—read now.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results